CrowdStrike Announces Real Time Response and Real Time Query to Help Organizations Get Back to Business Quickly After a Cyber Attack
CrowdStrike® Inc., the leader in cloud-delivered endpoint protection, today announced the addition of Real Time Response and Real Time Query features to its Falcon Insight™ EDR solution. These new features empower incident responders with immediate access to systems across the distributed enterprise so that they can rapidly investigate incidents, take decisive action to eradicate threats with surgical precision and get back to business quickly. The new features build on the CrowdStrike Falcon platform’s capability to stop threats on endpoints by adding unparalleled ability to respond quickly and minimize costs associated with handling advanced cyber attacks.
When a cyber attack is discovered, Security Operations Center (SOC) teams have two urgent goals: to understand the threat quickly and then, to take action to remediate it. According to CrowdStrike’s 2018 Global Threat Report, the average intrusion takes less than two hours to pivot from an initial point of attack toward the ultimate objective. This “breakout time” statistic shows how little time defenders have to investigate and eject the attacker from the network, before the incident escalates into a breach. Beyond its market-leading prevention capabilities, CrowdStrike addresses this challenge by providing deep, direct access to all the systems responders need to accomplish quick and effective remediation within the “breakout time” window.
By leveraging the existing Falcon sensor, cloud and console, CrowdStrike is able to deliver Real Time Response and Real Time Query capabilities to systems anywhere in the world, with no incremental cost in terms of performance or infrastructure. CrowdStrike Falcon’s EDR capabilities ensure customers have comprehensive, real-time and historical visibility of everything that is executed in their environment. The Real Time Response feature adds powerful interactive capabilities, delivering instant visibility into the local file system, registry, network, and more. It also allows responders to close the door on threats by killing malicious processes and removing remaining traces left behind by the attacker. Real Time Query delivers the ultimate visibility and control to responders, empowering them through custom-tailored information collection and response actions.
“With the launch of this capability, CrowdStrike is empowering SOC teams to remediate security-related incidents faster, more effectively, and more efficiently than ever before,” says George Kurtz, CrowdStrike’s co-founder and chief executive officer. “CrowdStrike Falcon Insight Real Time Response and Real Time Query help customers be more strategic with their incident response efforts, take decisive remediation steps quickly to minimize damage from cyber incidents, while operating with full knowledge of what is happening in their environment.”
For more information about CrowdStrike’s Spring Platform launch, read a blog by George Kurtz, CrowdStrike’s CEO, here.
Visit CrowdStrike during the RSA Conference 2018 at booth #941 Moscone South to see presentations and demos and meet with our experts.
About CrowdStrike®
CrowdStrike is the leader in cloud-delivered endpoint protection. Leveraging artificial intelligence (AI), the CrowdStrike Falcon® platform offers instant visibility and protection across the enterprise and prevents attacks on endpoints on or off the network. CrowdStrike Falcon deploys in minutes to deliver actionable intelligence and real-time protection from Day One. It seamlessly unifies next-generation AV with best-in-class endpoint detection and response, backed by 24/7 managed hunting. Its cloud infrastructure and single-agent architecture take away complexity and add scalability, manageability, and speed.
CrowdStrike Falcon protects customers against all cyber attack types, using sophisticated signatureless AI and Indicator-of-Attack (IOA) based threat prevention to stop known and unknown threats in real time. Powered by the CrowdStrike Threat Graph™, Falcon instantly correlates over 100 billion security events a day from across the globe to immediately prevent and detect threats.
There’s much more to the story of how Falcon has redefined endpoint protection but there’s only one thing to remember about CrowdStrike: We stop breaches.
You can gain full access to CrowdStrike Falcon Prevent™ by starting your free trial here.
Learn more: https://www.crowdstrike.com/
Follow
us: Blog
| Twitter
© 2018 CrowdStrike, Inc. All rights reserved. CrowdStrike®, CrowdStrike Falcon®, CrowdStrike Threat Graph™, CrowdStrike Falcon Prevent™, Falcon Prevent™, CrowdStrike Falcon Insight™, Falcon Insight™, CrowdStrike Falcon Discover™, Falcon Discover™, CrowdStrike Falcon Intelligence™, Falcon Intelligence™, CrowdStrike Falcon DNS™, Falcon DNS™, CrowdStrike Falcon OverWatch™, Falcon OverWatch™, CrowdStrike Falcon Spotlight™ and Falcon Spotlight™ are among the trademarks of CrowdStrike, Inc. Other brands may be third-party trademarks.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180416005407/en/
Contact information
CrowdStrike, Inc.
Ilina Cashiola, 202-340-0517
Ilina.cashiola@crowdstrike.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom